Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

Ignore the ‘superpower’ boasts – UK pharma looks superchallenged

NHS crisis, withdrawal of tax credits and exit from EU blamed for fall in UK share of R&D market

The Guardian - UK

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.

Investors Business Daily

Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Stock Slips Lower As FDA Rejects Fast Track Approval For Alzheimer's Drug

"We are committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need," Eli Lilly said.

The Street

Stocks Mixed, Netflix, Costco, Nordstrom, Eli Lilly In Focus - Five Things To Know

Stock futures mixed with Fed talk, earnings in focus; Netflix surges as blowout subscriber gains offset earnings miss; Costco shares gain as bulk retail unveils $4 billion buyback plan; Nordstrom slumps after slashing profit forecast following weak holiday sales and Eli Lilly slides as FDA rejects fast track review of…

The Street

Drugmakers sued over insulin prices

California's Attorney General Rob Bonta sued the six major companies that dominate the U.S. insulin market

Salon

How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly

The Food and Drug Administration expanded the label for Novo Nordisk's oral diabetes medicine, leading NVO stock to jump Friday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

California latest to sue drug companies over insulin prices

California says it will sue the companies that make and promote much of the nation's insulin

The Independent UK

2023 could be a banner year for prescription drugs

There's a large pipeline of promising yet expensive drugs that could get approved.

Axios

Tesla share plunge puts market cap behind LVMH, Nvidia, Eli Lilly

Tesla shares fell 12.2% on Tuesday after missing expectations on fourth-quarter deliveries.

Fortune

Dow Jones Futures Rise With Key Data Due After Market Hit Resistance To Start 2023

Dow Jones futures: The market started 2023 where it left off: flashes of strength with reversals at resistance. Apple and Tesla stock dived.

Investors Business Daily

IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock

Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.

Investors Business Daily

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock

Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.

Investors Business Daily

Only 9 Big Growth Stocks Are Still Up This Year — Do You Own Any?

Apple, Amazon and Nvidia might pop into your head when you think S&P 500 growth stocks. But that's not where the growth is now.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, Amgen

Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.

Axios

The growing market for weight loss drugs

A new generation of FDA-approved diabetes drugs that can also help patients lose weight has prompted enthusiasm from doctors and a firestorm of demand among patients so strong it's led to shortages.

The Independent UK

Twitter to re-launch blue tick subscription service after first chaotic rollout backfired

The platform’s Blue subscriptions will return with $8 monthly charges, or $11 a month for iPhone users

Investors Business Daily

How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again

A key decision from Eli Lilly could alight the obesity treatment landscape again, an analyst said Friday as LLY stock lingers near a record.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Here's What We Know So Far About Amgen's Obesity Drug As It Trails Novo Nordisk, Eli Lilly

Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.

Fortune

Top executives explain how they achieve ESG goals amid backlash

How should companies reframe ESG initiatives amid controversy? These executives offer their strategies.

The Street

These 10 Stocks Have Resilient Profit Margins

These stocks make sense, given the relatively flat forecast for stocks over the next six months by Goldman strategists.

Investors Business Daily

Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly

Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.

WEKU

Twitter has lost 50 of its top 100 advertisers since Elon Musk took over, report says

Half of Twitter's top 100 advertisers appear to no longer be advertising on the website. A new report states that these 50 advertisers have spent almost $2 billion on Twitter ads since 2020.

The Conversation

Elon Musk's Twitter Blue fiasco: Governments need to better regulate how companies use trademarks

Until recently, Twitter’s blue checkmark logo was (for better or worse) a trusted mark of authenticity. But under the façade of democratizing the platform, Elon Musk allowed the blue checkmark to be purchased by anyone — with unsurprisingly chaotic results.

The Guardian - US

‘More work to do’: Eli Lilly admits insulin pricing could be lower amid Twitter chaos

Furor over platform’s verified profiles may have done some good, but challenges still plague the site after a mass worker exodus

1 … 19 20 21 22

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.